sorivudine Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Sorivudine (INN), is a nucleoside analogue antiviral drug, marketed under trade names such as Usevir and Brovavir (BMS). It is used for the treatment of varicella zoster virus infections.   Wikipedia

Chemistry

  • SMILES: O=c1[nH]c(=O)n([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)cc1/C=C/Br
  • InChIKey: GCQYYIHYQMVWLT-HQNLTJAPSA-N
  • Mol. Mass: 349.14
  • ALogP: -1.49
  • ChEMBL Molecule:
    sorivudine  
More Chemistry

Pharmacology

Alternative names

1-beta-d-arabinofuranosyl-5-(2-bromovinyl)uracil | 1-beta-d-arabinofuranosyl-e-5-(2-bromovinyl)uracil | 2,4(1h,3h)-pyrimidinedione, 1-beta-d-arabinofuranosyl-5-(2-bromoethenyl)-, (e)- | 5-(2-bromovinyl)-1-beta-d-arabinofuranosyluracil | bravavir | brovavir | bv-arau | bv-ara-u | so-32756 | sorivudine | yn-72

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)


 

Chickenpox (Phase 3)

Herpes Zoster (Phase 2)

HIV Infections (Phase 3)

Neuralgia, Postherpetic (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue